Literature DB >> 27207428

Activated protein C promotes neuroprotection: mechanisms and translation to the clinic.

John H Griffin1, José A Fernández2, Patrick D Lyden3, Berislav V Zlokovic4.   

Abstract

Activated protein C (APC) is a plasma serine protease that is capable of antithrombotic, anti-inflammatory, anti-apoptotic, and cell-signaling activities. Animal injury studies show that recombinant APC and some of its mutants are remarkably therapeutic for a wide range of injuries. In particular, for neurologic injuries, APC reduces damage caused by ischemia/reperfusion in the brain, by acute brain trauma, and by chronic neurodegenerative conditions. For these neuroprotective effects, APC requires endothelial cell protein C receptor. APC activates cell signaling networks with alterations in gene expression profiles by activating protease activated receptors 1 and 3. To minimize APC-induced bleeding risk, APC variants were engineered to lack > 90% anticoagulant activity but retain normal cell signaling. The neuroprotective APC mutant, 3K3A-APC which has Lys191-193 mutated to Ala191-193, is very neuroprotective and it is currently in clinical trials for ischemic stroke.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  activated protein C (APC); neurogenesis; neuroprotection; stroke; traumatic brain injury

Mesh:

Substances:

Year:  2016        PMID: 27207428      PMCID: PMC4904825          DOI: 10.1016/S0049-3848(16)30368-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  54 in total

1.  Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis.

Authors:  D E Joyce; L Gelbert; A Ciaccia; B DeHoff; B W Grinnell
Journal:  J Biol Chem       Date:  2001-02-05       Impact factor: 5.157

Review 2.  Activated protein C based therapeutic strategies in chronic diseases.

Authors:  Fabian Bock; Khurrum Shahzad; Nathalie Vergnolle; Berend Isermann
Journal:  Thromb Haemost       Date:  2014-03-20       Impact factor: 5.249

Review 3.  Protease-activated receptor signalling by coagulation proteases in endothelial cells.

Authors:  Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2014-07-03       Impact factor: 5.249

Review 4.  Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency.

Authors:  M Dreyfus; M Masterson; M David; G E Rivard; F M Müller; W Kreuz; T Beeg; A Minford; J Allgrove; J D Cohen
Journal:  Semin Thromb Hemost       Date:  1995       Impact factor: 4.180

Review 5.  Activated protein C: A regulator of human skin epidermal keratinocyte function.

Authors:  Kelly McKelvey; Christopher John Jackson; Meilang Xue
Journal:  World J Biol Chem       Date:  2014-05-26

6.  Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.

Authors:  M Shibata; S R Kumar; A Amar; J A Fernandez; F Hofman; J H Griffin; B V Zlokovic
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

7.  Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Authors:  Zhihui Zhong; Hristelina Ilieva; Lee Hallagan; Robert Bell; Itender Singh; Nicole Paquette; Meenakshisundaram Thiyagarajan; Rashid Deane; Jose A Fernandez; Steven Lane; Anna B Zlokovic; Todd Liu; John H Griffin; Nienwen Chow; Francis J Castellino; Konstantin Stojanovic; Don W Cleveland; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

8.  Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1.

Authors:  Meenakshisundaram Thiyagarajan; José A Fernández; Steven M Lane; John H Griffin; Berislav V Zlokovic
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

9.  Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3.

Authors:  Huang Guo; Dong Liu; Harris Gelbard; Tong Cheng; Rae Insalaco; José A Fernández; John H Griffin; Berislav V Zlokovic
Journal:  Neuron       Date:  2004-02-19       Impact factor: 17.173

Review 10.  Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke.

Authors:  Arun Paul Amar; John H Griffin; Berislav V Zlokovic
Journal:  Front Cell Neurosci       Date:  2015-09-02       Impact factor: 5.505

View more
  16 in total

1.  Neuroprotection and vasculoprotection using genetically targeted protease-ligands.

Authors:  Padmesh S Rajput; Jessica A Lamb; Jose Á Fernández; Jilin Bai; Benedict R Pereira; I-Farn Lei; Jennifer Leung; John H Griffin; Patrick D Lyden
Journal:  Brain Res       Date:  2019-03-14       Impact factor: 3.252

Review 2.  Pharmacological Enhancement of Stroke Recovery.

Authors:  Amit Kumar; Tomoko Kitago
Journal:  Curr Neurol Neurosci Rep       Date:  2019-05-30       Impact factor: 5.081

Review 3.  Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature.

Authors:  Sherief Ghozy; Abdullah Reda; Joseph Varney; Ahmed Sallam Elhawary; Jaffer Shah; Kimberly Murry; Mohamed Gomaa Sobeeh; Sandeep S Nayak; Ahmed Y Azzam; Waleed Brinjikji; Ramanathan Kadirvel; David F Kallmes
Journal:  Front Neurol       Date:  2022-05-31       Impact factor: 4.086

Review 4.  2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

Authors:  John H Griffin; Laurent O Mosnier; José A Fernández; Berislav V Zlokovic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-06       Impact factor: 8.311

5.  Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.

Authors:  Patrick Lyden; Kent E Pryor; Christopher S Coffey; Merit Cudkowicz; Robin Conwit; Ashutosh Jadhav; Robert N Sawyer; Jan Claassen; Opeolu Adeoye; Shlee Song; Peter Hannon; Natalia S Rost; Archana Hinduja; Michel Torbey; Jin-Moo Lee; Curtis Benesch; Michael Rippee; Marilyn Rymer; Michael T Froehler; E Clarke Haley; Mark Johnson; Jon Yankey; Kim Magee; Julie Qidwai; Howard Levy; E Mark Haacke; Miller Fawaz; Thomas P Davis; Arthur W Toga; John H Griffin; Berislav V Zlokovic
Journal:  Ann Neurol       Date:  2019-01-07       Impact factor: 10.422

6.  Evaluation of 3K3A-Activated Protein C to Treat Neonatal Hypoxic Ischemic Brain Injury in the Spiny Mouse.

Authors:  Stacey J Ellery; Madeleine G Goss; Nadine Brew; Hayley Dickinson; Nadia Hale; Domenic A LaRosa; David W Walker; Flora Y Wong
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

7.  Rational Design of Protein C Activators.

Authors:  Sergio Barranco-Medina; Mary Murphy; Leslie Pelc; Zhiwei Chen; Enrico Di Cera; Nicola Pozzi
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

Review 8.  Cerebroprotection for Acute Ischemic Stroke: Looking Ahead.

Authors:  Patrick D Lyden
Journal:  Stroke       Date:  2021-07-22       Impact factor: 10.170

Review 9.  Activated protein C, protease activated receptor 1, and neuroprotection.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Blood       Date:  2018-06-04       Impact factor: 25.476

10.  PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.

Authors:  Ranjeet K Sinha; Yaoming Wang; Zhen Zhao; Xiao Xu; Laurent Burnier; Naveen Gupta; José A Fernández; Greg Martin; Sergey Kupriyanov; Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Blood       Date:  2018-01-17       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.